In summary, we believe that GPS1, as a transcriptional co-activator, can promote the malignant behavior of breast cancer by interacting with WBP2 to prepare the "molecular soil" for cellular response to Wnt signaling; the interaction between GPS1 expression and the immune microenvironment may provide a new target for immunotherapy. The gene discussed is WBP2; the disease is breast carcinoma.